Allogeneic Stem Cell Therapy for Acute Ischemic Stroke: The Phase 2/3 TREASURE Randomized Clinical Trial.,JAMA Neurology

当前位置： X-MOL 学术 › JAMA Neurol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Allogeneic Stem Cell Therapy for Acute Ischemic Stroke: The Phase 2/3 TREASURE Randomized Clinical Trial.
JAMA Neurology ( IF 29.0 ) Pub Date : 2024-01-16 , DOI: 10.1001/jamaneurol.2023.5200
Kiyohiro Houkin ₁ , Toshiya Osanai ₂ , Shinichiro Uchiyama _{3,

4} , Kazuo Minematsu ₅ , Akihiko Taguchi ₆ , Katsuhiko Maruichi ₇ , Yoshimasa Niiya ₈ , Katsuyuki Asaoka ₉ , Yoshihiro Kuga ₁₀ , Katsumi Takizawa ₁₁ , Koichi Haraguchi ₁₂ , Shinichi Yoshimura ₁₃ , Kazumi Kimura ₁₄ , Koji Tokunaga ₁₅ , Atsuo Aoyama ₁₆ , Fusao Ikawa ₁₇ , Chikanori Inenaga ₁₈ , Tatsuya Abe ₁₉ , Atsushi Tominaga ₂₀ , Shinichi Takahashi ₂₁ , Kohsuke Kudo ₂₂ , Miki Fujimura ₂ , Taku Sugiyama ₂ , Masaki Ito ₂ , Masahito Kawabori ₂ , David C. Hess ₂₃ , Sean I. Savitz ₂₄ , Teruyuki Hirano ₂₅ , Kiyohiro Houkin ₂₆ , Toshiya Osanai ₂₆ , Katsuhiko Maruichi ₂₆ , Yoshimasa Niiya ₂₆ , Katsuyuki Asaoka ₂₆ , Katsumi Takizawa ₂₆ , Kouichi Haraguchi ₂₆ , Rokuya Tanikawa ₂₆ , Akira Tempaku ₂₆ , Yusuke Shimoda ₂₆ , Masanori Isobe ₂₆ , Kenji Kamiyama ₂₆ , Masafumi Ohtaki ₂₆ , Norihito Shimamura ₂₆ , Junta Moroi ₂₆ , Aiki Marushima ₂₆ , Shinichi Takahashi ₂₆ , Takao Urabe ₂₆ , Teruyuki Hirano ₂₆ , Kazumi Kimura ₂₆ , Kazuo Kitagawa ₂₆ , Hidetoshi Kasuya ₂₆ , Yoshikane Izawa ₂₆ , Yasuyuki Iguchi ₂₆ , Koichi Oki ₂₆ , Koichi Kato ₂₆ , Yoshihisa Yamano ₂₆ , Satoshi Kuroda ₂₆ , Atsushi Sato ₂₆ , Chikanori Inenaga ₂₆ , Keizo Yasui ₂₆ , Kazunori Toyoda ₂₆ , Shinichi Yoshimura ₂₆ , Nobuyuki Sakai ₂₆ , Yoshihiro Kuga ₂₆ , Atsuo Aoyama ₂₆ , Fusao Ikawa ₂₆ , Koji Tokunaga ₂₆ , Atsushi Tominaga ₂₆ , Yasushi Takagi ₂₆ , Masahiro Yasaka ₂₆ , Tatsuya Abe ₂₆ , Takayuki Matsuo ₂₆ , Toshiro Yonehara ₂₆ , Tadashi Terasaki ₂₆ , Hideki Matsuoka ₂₆ ,

Affiliation

Hokkaido University, Sapporo, Japan
Department of Neurosurgery, Hokkaido University, Sapporo, Japan
Clinical Research Center for Medicine, International University of Health and Welfare, Tokyo, Japan
Center for Brain and Cerebral Vessels, Sanno Medical Center, Tokyo, Japan
Iseikai International General Hospital, Osaka City, Japan
Department of Regenerative Medicine Research, Foundation for Biomedical Research and Innovation at Kobe, Kobe, Japan
Department of Neurosurgery, Kashiwaba Neurosurgical Hospital, Sapporo, Japan
Department of Neurosurgery, Otaru General Hospital, Otaru, Japan
Department of Neurosurgery, Teine Keijinkai Medical Center, Sapporo, Japan
Department of Neurosurgery, Ohnishi Neurological Center, Akashi, Japan
Department of Neurosurgery, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan
Department of Neurosurgery, Hakodate Shintoshi Hospital, Hakodate, Japan
Department of Neurosurgery, Hyogo Medical University, Nishinomiya, Japan
Department of Neurology, Nippon Medical School Hospital, Tokyo, Japan
Department of Neurosurgery, Okayama City Hospital, Okayama City, Japan
Department of Neurology, Shimane Prefectural Central Hospital, Izumo, Japan
Department of Neurosurgery, Shimane Prefectural Central Hospital, Izumo, Japan
Department of Neurosurgery, Seirei Hamamatsu General Hospital, Hamamatsu, Japan
Department of Neurosurgery, Saga University, Nabeshima, Japan
Department of Neurosurgery and Neuroendovascular Therapy, Hiroshima Prefectural Hospital, Hiroshima City, Japan
Department of Neurology and Stroke, Saitama Medical University International Medical Center, Hidaka, Japan
Department of Diagnostic Imaging, Hokkaido University, Sapporo, Japan
Department of Neurology, Medical College of Georgia, Augusta University, Augusta
Department of Neurology Institute for Stroke and Cerebrovascular Disease, UTHealth, Houston, Texas
Department of Stroke and Cerebrovascular Medicine, Kyorin University, Mitaka, Japan
for the TREASURE Study Investigators

Cell therapy is a promising treatment approach for stroke and other diseases. However, it is unknown whether MultiStem (HLCM051), a bone marrow-derived, allogeneic, multipotent adult progenitor cell product, has the potential to treat ischemic stroke.

中文翻译：